Hypoglycemic Drugs Market, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Drug Class (Sulphonylureas, Biguanides, Alpha-glucosidase inhibitors, Thiazolidinediones (Glitazones), Dipeptidyl peptidase-4 (DPP-4) inhibitors, and Glucagon), By Administration Route (Oral, Injectable, and Nasal), By Region Analysis - Global Analysis And Industry Forecast Report Till 2030.

The Global Hypoglycemic Drugs Market is projected to grow from $50.2 billion to $83.3 billion, at a CAGR of 5.9% in terms of revenue during the forecast period 2021-2030.

Hypoglycemia is a state of having blood sugar (glucose) levels that are below normal. Glucose acts as the primary source of energy for the body. Hypoglycemia and diabetes management frequently go hand in hand. When the blood glucose level drops below a predetermined threshold, such as below 4 mmol/L (72 mg/dL), hypoglycemia results.

Sweating, fatigue, feeling woozy, lethargic, blurred vision, and ammeters are hypoglycemic signs. Using a glucose metre to measure blood sugar levels, characterized can be identified. Hypoglycemia is characterised by a blood glucose level below 4.0 mmol/L.

Market Dynamics:

Drivers:

The adoption of second-generation glucagons in nasal and liquid-stable formulations, as well as the introduction of the first therapy for post-bariatric hypoglycemia, are the main factors driving the rise in the market for hypoglycemia medications. The first medication was designed specifically to treat PBHSinceet during the forecast time. Due to the fact that this is a targeted treatment, it will be able to garner a sizable market share and will eventually fuel the market's expansion. The global market for hypoglycemic drugs is anticipated to expand as a result of an increasing number of drug approvals from regulatory bodies.

Restraints:

The global market for hypoglycemic drugs is predicted to experience growth barriers due to market participants' drug recalls. As an illustration, the US FDA informed patients and medical personnel about Nostrum Laboratories' voluntary recall of a second lot of extended-release (ER) metformin in June 2021. The batch of metformin had been recalled by the manufacturer because it might have contained N-nitroso dimethylamine (NDMA) over the allowable intake limit.

Opportunities:

The global market for hypoglycemic drugs is anticipated to expand due to the rising prevalence of diabetes. For instance, a July 2022 article from the American Diabetes Association stated that in 2019, there were 37.3 million People who had diabetes, or about 11.3% of the population. Almost 1.9 million Americans, including about 244,000 toddlers and teenagers, had type 1 diabetes. According to the same source, 1.4 million people receive a diabetes diagnosis each year. This might open up a lot of different market possibilities.               

Key Players:

• Eli Lilly & Company

• Company Overview

• Product Portfolio

• Financial Performance

• Recent Highlights

• Strategies

• Boehringer Ingelheim GmbH

• Vistin Pharma AS

• Janssen Pharmaceuticals NV

• Sanofi

• Astellas Pharma Inc.

• AstraZeneca plc.

• Merck & Co., Inc.

• Novartis AG

• Novo Nordisk A/S

• Teva Pharmaceuticals Pvt Ltd.

• Sun Pharmaceutical Industries Ltd.

Market Segmentation:

Hypoglycemic Drugs Market, By Drug Class

• Sulphonylureas

• Biguanides

• Alpha-glucosidase inhibitors

• Thiazolidinediones (Glitazones)

• Dipeptidyl peptidase-4 (DPP-4) inhibitors

• Glucagon

Hypoglycemic Drugs Market, By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

 Hypoglycemic Drugs Market, By Administration Route

• Oral

• Injectable

• Nasal

 Hypoglycemic Drugs Market, By Region Type

• North America 

• Europe 

• Asia-Pacific 

• LAMEA 

Regional Analysis:

North America, which brought in USD XX Million from the diabetes drugs market in 2021, is anticipated to rule the market for the entire projection period. Many government organizations are investing more money in research and development, and a rise in the prevalence of diabetes is one of the factors that is expected to contribute significantly to the market share of diabetes drugs in North America. Additionally, favorable reimbursement policies, new launches of anti-diabetic drugs, and increasing public knowledge of novel anti-diabetic medications all have the potential to positively impact the diabetic drug market in North America.

Asia-Pacific is anticipated to account for the fastest-growing market in the coming years, according to geographical estimates. Due to increased technological development and rising healthcare costs, it is surpassing Europe as the second-largest market.

Scope of the report:

User

Tab Content